CMV Colitis: A Rare Complication of Azacitidine and Venetoclax Chemotherapy
Herein, we present a case of cytomegalovirus (CMV) colitis that occurred after two cycles of azacitidine and venetoclax in a 64-year-old woman affected with acute myeloid leukaemia (AML) secondary to a previous diagnosis of a hypoplastic myelodysplastic syndrome (hypo-MDS). This patient never had de...
Main Authors: | Mustafa Nissar Bankur, Archie Keeling, Khoodoruth Mohamed Adil Shah, Daniele Avenoso |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Hematology Reports |
Subjects: | |
Online Access: | https://www.mdpi.com/2038-8330/14/3/29 |
Similar Items
-
AMP-Activated Protein Kinase Contributes to Apoptosis Induced by the Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia
by: Noémie Legrand, et al.
Published: (2021-11-01) -
Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?
by: Ramy Rahmé, et al.
Published: (2024-01-01) -
Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology
by: Dmitry Zhigarev, et al.
Published: (2022-07-01) -
Abivertinib synergistically strengthens the anti‐leukemia activity of venetoclax in acute myeloid leukemia in a BTK‐dependent manner
by: Shujuan Huang, et al.
Published: (2020-10-01) -
Review of Venetoclax in CLL, AML and Multiple Myeloma
by: Masa Lasica, et al.
Published: (2021-05-01)